Pathogenic *NOTCH3* Variants Are Frequent Among the Korean General Population

Chul-Hoo Kang, MD,* Young Mee Kim, PhD,* Yang-Ji Kim, MS, Su-Jeong Hong, MS, Do Yoon Kim, BS, Hyun Goo Woo, MD, PhD, Young Ree Kim, MD, PhD, Joong-Goo Kim, MD, Jung Seok Lee, MD, Mi Hee Kong, MD, PhD, Hyeon Ju Kim, MD, and Jay Chol Choi, MD, PhD

Correspondence
Dr. Choi
jaychoi@jejunu.ac.kr

Abstract

Objective
This study aimed to determine the frequency of pathogenic *NOTCH3* variants among Koreans.

Methods
In this cross-sectional study, we queried for pathogenic *NOTCH3* variants in 2 Korean public genome databases: the Korean Reference Genome Database (KRGDB) and the Korean Genome Project (Korea1K). In addition, we screened the 3 most common pathogenic *NOTCH3* variants (p.Arg75Pro, p.Arg544Cys, and p.Arg578Cys) for 1,000 individuals on Jeju Island, where the largest number of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) have been reported in Korea.

Results
The pathogenic *NOTCH3* variant (p.Arg544Cys) was found in 0.12% of sequences in the KRGDB, and 3 pathogenic variants (p.Arg75Pro, p.Arg182Cys, and p.Arg544Cys) were present in 0.44% of the Korea1K database. Of the 1,000 individuals on Jeju Island, we found 2 cysteine-altering *NOTCH3* variants (p.Arg544Cys variant in 9 and p.Arg578Cys in 1 individual) in 1.00% of the participants (95% confidence interval: 0.48%–1.83%). The presence of cysteine-altering *NOTCH3* variants was significantly associated with a history of stroke ($p < 0.001$).

Discussion
Pathogenic *NOTCH3* variants are frequently found in the general Korean population. Such a high prevalence of pathogenic variants could threaten the brain health of tens of thousands to hundreds of thousands of older adults in Korea.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) was known as a rare genetic disorder with an estimated prevalence of 2–5/100,000.[1,2] However, recent genomic database research clearly indicates an estimated global mutation prevalence of 3.4/1,000, much higher than that estimated previously.[3] In particular, the East or South Asian regions showed the highest frequency of cysteine-altering *NOTCH3* mutations with a prevalence of 9.0–11.7/1,000 individuals. This study aimed to determine the frequency of pathogenic *NOTCH3* variants among Koreans.

Methods

Korean Public Genome Database Query

We queried for pathogenic *NOTCH3* variants associated with CADASIL in 2 publicly available Korean genome databases: the Korean Reference Genome Database (KRGDB) and the Korean Genome Project (Korea1K).[4,5] The KRGDB was established by the Korean National Institute of Health and contains whole-genome data for 1,722 participants from various cohorts. The Korea1K data set included whole-genome data of 1,094 healthy individuals, mostly from the Ulsan metropolitan region located in the southern part of the Korean peninsula. ANNOVAR bioinformatics software was used for annotating any rare nonsynonymous variants, including missense, inframe insertion/deletion, frameshift, start gain/loss, stop gain/loss, and splice site variants in the *NOTCH3* gene.[6] In this study, a minor allele frequency <0.01 was defined as a rare variant. Among the rare variants retrieved from the database, we defined the variant as pathogenic if it was associated with CADASIL and classified as pathogenic or likely pathogenic in ClinVar (ncbi.nlm.nih.gov/clinvar/).

Screening for *NOTCH3* Variants Among 1,000 Individuals Living on Jeju Island

Of the 4,350 anonymized genomic DNA samples, a randomly selected 1,000 samples with their health information were provided by the Biobank of Jeju National University Hospital, a member of the Korea Biobank Network. This study was approved by the Institutional Review Board of Jeju National University Hospital (IRB File No. JEJUNUH 2020-09-006). Informed consent was obtained at the time of DNA donation to the Biobank. We screened the 3 most frequently found *NOTCH3* mutations on Jeju Island: p.Arg75Pro (c.244G>C),

p.Arg544Cys (c.1630>T), and p.Arg578Cys (c.1732C>T). Other detailed information for the PCR, sequencing, and statistical analysis was provided as Supplemental Material, links.lww.com/NXG/A495.

Results

Pathogenic *NOTCH3* Variants in 2 Korean Public Genome Databases

Three pathogenic *NOTCH3* variants associated with CADASIL, p.Arg75Pro (c.224G>C), p.Arg182Cys (c.544C>T), and p.Arg544Cys (c.1630C>T), were found in 2 Korean public genome databases. In the KRGDB with 1,722 participants, only the p.Arg544Cys variant was identified with a carrier frequency of 0.12%. Three pathogenic variants (p.Arg75Pro, p.Arg182Cys, and p.Arg544Cys) were present in the Korea1K database with 1,094 individuals, and the carrier frequencies were 0.22, 0.11, and 0.11%, respectively. Only the p.Arg544Cys variant was discovered in common (Table 1).

Screening Pathogenic *NOTCH3* Variants in 1,000 Individuals on Jeju Island

Of 1,000 individuals on Jeju Island, 3 had a history of stroke, and 6.6% had a family history of stroke. We found 2 cysteine-altering *NOTCH3* variants in 1.00% of the participants with a 95% confidence interval of 0.48–1.83% (p.Arg544Cys mutation in 9 individuals and p.Arg578Cys in 1). Compared with individuals without pathogenic *NOTCH3* variants, those with the variants were more likely to have a history of stroke ($p < 0.001$) (Table 2). Of the 10 individuals with pathogenic variants, 2 participants underwent a brain MRI examination (eTable 3, links.lww.com/NXG/A495 and Figure).

Discussion

A recent study from Taiwan reported a very high prevalence of cysteine-altering *NOTCH3* variants among Taiwanese (9/1,000), and the study also suggested that the cysteine-altering variant resulted in a 3.40-fold increased risk for stroke and even an 11.05-fold increased risk for small-vessel stroke.[7] In line with the Taiwanese study, this study suggested a high prevalence of pathogenic *NOTCH3* variants among the general Korean population, with an estimated number of carriers ranging from 1.2/1,000 to 4.4/1,000. On Jeju Island, located

Table 1 Prevalence of Pathogenic *NOTCH3* Variants in 2 Korean Public Genome Databases and 1,000 Individuals Living on Jeju Island

	KRGDB	Korea 1K	Jeju screening study
Number of participants	1,722	1,094	1,000
***NOTCH3* variant frequency**	p.Arg544Cys (0.12%)	p.Arg75Pro (0.22%) p.Arg544Cys (0.11%) p.Arg182Cys (0.11%)	p.Arg544Cys (0.90%) p.Arg578Cys (0.10%)

Abbreviation: KRGDB = Korean Reference Genome Database.

Table 2 Baseline Characteristics of the Jeju Participants

	No variants (n = 990)	Variants (n = 10)	Total (N = 1,000)	*p* Value
Demographic				
Age, y	49.9 ± 11.3	51.9 ± 14.5	49.9 ± 11.3	0.573
Male	454 (45.4)	6 (60.0)	460 (46.0)	0.373
Height, cm	164.6 ± 8.5	165.8 ± 6.3	164.6 ± 8.5	0.661
Weight, kg	64.1 ± 11.6	63.1 ± 8.3	64.1 ± 11.6	0.771
Vascular risk factors				
Hypertension	4 (0.4)	0 (0.0)	4 (0.4)	0.841
DM	0 (0.0)	0 (0.0)	0 (0.0)	—
Hyperlipidemia	38 (3.8)	0 (0.0)	38 (3.8)	0.528
Smoking	256 (25.9)	2 (20.0)	258 (25.8)	0.674
Medical history				
Stroke	0 (0.0)	3 (30.0)	3 (0.3)	<0.001
Ischemic heart disease	4 (0.4)	0 (0.0)	4 (0.4)	0.841
Family history				
Stroke	65 (6.6)	1 (10.0)	66 (6.6)	0.664
Laboratory finding				
Systolic blood pressure, mm Hg	117.8 ± 11.5	118.7 ± 10.2	117.8 ± 11.5	0.800
Diastolic blood pressure, mm Hg	74.1 ± 8.2	74.9 ± 8.9	74.1 ± 8.2	0.756
White blood cell, k/mm^3	5.4 ± 1.5	4.5 ± 0.7	5.4 ± 1.5	0.045
Hemoglobin, g/dL	14.0 ± 1.7	14.1 ± 1.4	14.0 ± 1.7	0.943
Platelet count, k/mm^3	250.3 ± 56.2	240.6 ± 33.9	250.2 ± 56.1	0.586
BUN, mg/dL	12.0 ± 3.6	12.1 ± 3.2	12.0 ± 3.6	0.950
Creatinine, mg/dL	0.9 ± 0.2	1.0 ± 0.2	0.9 ± 0.2	0.935
Estimated GFR (IDMS-MDRD), mL/min/1.73 m^2	93.1 ± 15.8	95.3 ± 15.7	93.1 ± 15.8	0.812
Fasting glucose, mg/dL	89.9 ± 8.8	94.1 ± 11.7	90.0 ± 8.9	0.140
HbA1C, %	5.4 ± 0.4	5.4 ± 0.4	5.4 ± 0.4	0.970
CRP, mg/dL	0.13 ± 0.43	0.03 ± 0.01	0.13 ± 0.43	0.486
Homocysteine, mg/dL	8.5 ± 2.8	8.1 ± 1.2	8.5 ± 2.8	0.765
Total cholesterol, mg/dL	190.4 ± 26.1	172.0 ± 31.3	190.2 ± 26.2	0.028
LDL cholesterol, mg/dL	115.9 ± 24.0	110.3 ± 28.7	115.9 ± 24.0	0.494
HDL cholesterol, mg/dL	59.2 ± 14.3	48.0 ± 9.5	59.0 ± 14.3	0.014
Triglyceride, mg/dL	82.9 ± 36.8	77.0 ± 38.3	82.8 ± 36.8	0.614

Abbreviations: BUN, blood urea nitrogen; DM, diabetes mellitus; GFR, glomerular filtration rate; HDL, high-density lipoprotein; IDMS-MDRD, isotope dilution mass spectrometry–the modification of diet in renal disease; LDL, low-density lipoprotein.
Data are N (%), mean ± SD.
Data were compared using the Pearson χ^2 test, Fisher exact test, Student *t* test, or Wilcoxon rank-sum test according to the characteristics of the variables.

off the southern coast of the Korean peninsula with a current population of 670,000, the number of mutation carriers could reach 67,000, and they could be at increased risk of stroke or develop other symptoms reported in CADASIL. Long-term impact of harboring pathogenic *NOTCH3* variants in seemingly healthy young individuals needs to be investigated further.

Figure Brain MRI of the 2 Individuals With p.Arg544Cys Variants

Patient 2 is a 58-year-old man who had had an abrupt onset of mild dysarthria at age 54 years. Diffusion MRI at that time showed a small subacute infarction on the left frontal white matter (arrow) and multiple small white matter hyperintensity lesions on fluid attenuated inversion recovery images. Patient 3 is a 50-year-old man and received a brain MRI examination as a screening health checkup and had a few small subcortical white matter hyperintensity lesions and periventricular white matter lesions.

This study has several limitations. First, because of the limited sample size of the Korean public genome database and the Jeju screening study, this study was underpowered to prove whether the Korean general population has a high prevalence of pathogenic *NOTCH3* variants reported in the previous literature. Second, we screened only the 3 most frequently found pathogenic variants in the Jeju screening study. Therefore, we might miss other rare pathogenic variant associated with CADASIL in these 1,000 individuals.

Disclosure
Go to Neurology.org/NG for full disclsoures.

Appendix Authors

Name	Location	Contribution
Chul-Hoo Kang, MD	Department of Neurology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; additional contributions: this author contributed equally to the manuscript as the first author.

Appendix *(continued)*

Name	Location	Contribution
Young Mee Kim, PhD	Department of Biochemistry, School of Medicine, Jeju National University, Jeju, Korea	Drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data; additional contributions: this author contributed equally to the manuscript as the first author.
Yang-Ji Kim, MS	Institute of Medical Science, Jeju National University, Jeju, Korea	Major role in the acquisition of data and analysis or interpretation of data
Su-Jeong Hong, MS	Institute of Medical Science, Jeju National University, Jeju, Korea	Major role in the acquisition of data and analysis or interpretation of data
Do Yoon Kim, BS	Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea; Department of Biomedical Science, Graduate School, Ajou University, Suwon, Republic of Korea	Analysis or interpretation of data
Hyun Goo Woo, MD, PhD	Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea; Department of Biomedical Science, Graduate School, Ajou University, Suwon, Republic of Korea	Study concept or design
Young Ree Kim, MD, PhD	Department of Laboratory Medicine, Jeju National University School of Medicine, Jeju, Korea	Major role in the acquisition of data
Joong-Goo Kim, MD	Department of Neurology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea	Study concept or design

Appendix *(continued)*

Name	Location	Contribution
Jung Seok Lee, MD	Department of Neurology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea	Study concept or design
Mi Hee Kong, MD, PhD	Department of Family Medicine, Jeju National University Hospital, Jeju, Korea; Department of Family Medicine, Jeju National University School of Medicine, Jeju, Korea	Major role in the acquisition of data
Hyeon Ju Kim, MD	Department of Family Medicine, Jeju National University Hospital, Jeju, Korea; Department of Family Medicine, Jeju National University School of Medicine, Jeju, Korea	Major role in the acquisition of data

Appendix *(continued)*

Name	Location	Contribution
Jay Chol Choi, MD, PhD	Department of Neurology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea; Institute of Medical Science, Jeju National University, Jeju, Korea	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data

References

1. Choi JC. Genetics of cerebral small vessel disease. *J Stroke*. 2015;17(1):7-16.
2. Narayan SK, Gorman G, Kalaria RN, Ford GA, Chinnery PF. The minimum prevalence of CADASIL in northeast England. *Neurology*. 2012;78(13):1025-1027.
3. Rutten JW, Dauwerse HG, Gravesteijn G, et al. Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL. *Ann Clin Transl Neurol*. 2016;3(11):844-853.
4. Jeon S, Bhak Y, Choi Y, et al. Korean genome project: 1094 Korean personal genomes with clinical information. *Sci Adv*. 2020;6(22):eaaz7835.
5. Jung KS, Hong KW, Jo HY, et al. KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing. *Database*. 2020;2020:baz146 doi: 10.1093/database/baz146. Published: March 4, 2020.
6. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38(16):e164.
7. Lee YC, Chung CP, Chang MH, Wang SJ, Liao YC. NOTCH3 cysteine-altering variant is an important risk factor for stroke in the Taiwanese population. *Neurology*. 2020;94(1):e87-e96.